Docetaxel Combined with Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer

David E. Gerber, David R. Spigel, David Giorgadze, Mikhail Shtivelband, Olga V. Ponomarova, Joseph S. Shan, Kerstin B. Menander, Chandra P. Belani

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background Bavituximab is a phosphatidylserine-targeting antibody with a selective tumor, vascular-directed immune response. In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsquamous non-small-cell lung cancer were evaluated. Patients and Methods Patients were randomized 1:1:1 to receive docetaxel 75 mg/m2 every 21 days for up to 6 cycles combined with weekly, blinded infusions of placebo, bavituximab 1 mg/kg, or bavituximab 3 mg/kg until disease progression or unacceptable toxicity. The primary end point was overall response rate (ORR), with a predefined end point of 26% in the bavituximab arms. After study unblinding, vial-coding discrepancies were discovered in the placebo and bavituximab 1 mg/kg groups. In exploratory analyses, data from these groups were pooled to form the control group and compared with the 3 mg/kg group. Results Efficacy end points in the bavituximab 3 mg/kg group (n = 41) and in the placebo/bavituximab 1 mg/kg group (n = 80), respectively, were as follows: ORR, 17.1% (95% confidence interval [CI], 5.6%-28.6%) and ORR, 11.3% (95% CI, 4.3%-18.2%); median progression-free survival 4.5 and 3.3 months (hazard ratio [HR], 0.74 [95% CI, 0.45-1.21]; P =.24); median overall survival 11.7 and 7.3 months (HR, 0.66 [95% CI, 0.40-1.10]; P =.11). Toxicities were manageable and similar between arms. Conclusion The combination of bavituximab and docetaxel is well tolerated. Although no firm efficacy conclusions can be drawn and the trial did not meet the predefined primary end point, exploratory analyses suggest trends favoring the combination of bavituximab 3 mg/kg with docetaxel. This regimen is being evaluated in the ongoing, global, phase III SUNRISE trial.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalClinical Lung Cancer
Volume17
Issue number3
DOIs
StatePublished - May 1 2016

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Docetaxel Combined with Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this

    Gerber, D. E., Spigel, D. R., Giorgadze, D., Shtivelband, M., Ponomarova, O. V., Shan, J. S., Menander, K. B., & Belani, C. P. (2016). Docetaxel Combined with Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 17(3), 169-176. https://doi.org/10.1016/j.cllc.2016.02.003